'The lower the better' in hypercholesterolemia therapy: A reliable clinical guideline?

Annals of Internal Medicine

Volumn 133, Issue 7, 2000, Pages 549-554

  Jacobson, T A ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0034601809     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-7-200010030-00015     Document Type: Review

References (31)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
5. Seram cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study
6. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
7. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study
8. Maximizing the cost-effectiveness of lipid-lowering therapy
9. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
10. Range of serum cholesterol values in the population developing coronary artery disease
11. Prevalence of high blood cholesterol among US adults. An update from the second report of the National Cholesterol Education Program Adult Treatment Panel
12. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
13. The effect of aggressive lowering of low-density lipoprotein cholesterol and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators
14. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial
15. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators
16. Aggressive lipid-lowering therapy: A clinical imperative
17. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
18. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
19. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
20. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
21. Impact of evidence-based 'clinical judgment' on the number of American adults requiring lipid lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey
22. Prevention of coronary heart disease in clinical practice. Recommendation of the Second Joint Task Force of European and other Societies on Coronary Prevention
23. Cholesterol reduction and clinical benefit. Are there limits to our expectations?
24. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology
25. An updated coronary risk profile. A statement for health care professionals
26. Medical costs of coronary artery disease in the United States
27. Dose-response characteristics of cholesterol-lowering drug therapies: Implications for treatment
28. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin more cost-effective?
29. Diabetes, other risk facrors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
30. Management of dyslipidemia in adults with diabetes. Position statement. American Diabetes Association
31. New perspectives on the management of low levels of high-density lipoprotein cholesterol